HUP0202757A2 - Metabotróp glutamát receptor antagonista heteropoliciklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása - Google Patents

Metabotróp glutamát receptor antagonista heteropoliciklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása

Info

Publication number
HUP0202757A2
HUP0202757A2 HU0202757A HUP0202757A HUP0202757A2 HU P0202757 A2 HUP0202757 A2 HU P0202757A2 HU 0202757 A HU0202757 A HU 0202757A HU P0202757 A HUP0202757 A HU P0202757A HU P0202757 A2 HUP0202757 A2 HU P0202757A2
Authority
HU
Hungary
Prior art keywords
glutamate receptor
metabotropic glutamate
pharmaceutical compositions
compositions containing
receptor antagonists
Prior art date
Application number
HU0202757A
Other languages
English (en)
Inventor
Methvin Benjamin Isaac
Donald A. Mcleod
Scott T. Moe
Susan M. Sheehan
Abdelmalik Slassi
Daryl L. Smith
Thomas M. Strormann
Bradford C. Wagenen
Original Assignee
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202757(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharmaceuticals, Inc. filed Critical Nps Pharmaceuticals, Inc.
Publication of HUP0202757A2 publication Critical patent/HUP0202757A2/hu
Publication of HUP0202757A3 publication Critical patent/HUP0202757A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány metabotróp glutamát receptor antagonista hatásúvegyületekre vonatkozik, amelyek neurológiai és pszichiátriaimegbetegedések és rendellenességek kezelésére alkalmazhatók. Atalálmány szerinti (II) általános képletű vegyületekben X, Y és Zjelentése egymástól függetlenül nitrogén-, oxigén-, kén- vagy szénatomvagy karbonilcsoport, Ar1 és Ar2 jelentése egymástól függetlenül adottesetben helyettesített heterociklusos vagy kondenzált heterociklusoscsoport, amely a nitrogén- oxigén- és kénatomok közül választott 1-4heteroatomot tartalmaz, vagy a következő csoportból választott adottesetben helyettesített aromás csoport: fenil-, benzil-, 1-naftil-, 2-naftil-, fluorenil-, antrenil-, indenil-, fenantrenil-,benzonaftenilcsoport. Ó
HU0202757A 1999-08-19 2000-08-18 Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists HUP0202757A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0202757A2 true HUP0202757A2 (hu) 2002-12-28
HUP0202757A3 HUP0202757A3 (en) 2006-03-28

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202757A HUP0202757A3 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists

Country Status (28)

Country Link
EP (1) EP1210344B1 (hu)
JP (2) JP3790472B2 (hu)
KR (1) KR100875222B1 (hu)
CN (1) CN1313465C (hu)
AT (1) ATE307129T1 (hu)
AU (1) AU780191B2 (hu)
BG (1) BG65586B1 (hu)
BR (1) BR0013427A (hu)
CA (1) CA2381975A1 (hu)
CY (1) CY1105253T1 (hu)
CZ (1) CZ2002599A3 (hu)
DE (1) DE60023318T2 (hu)
DK (1) DK1210344T3 (hu)
EE (1) EE200200079A (hu)
ES (1) ES2250177T3 (hu)
HK (1) HK1047929A1 (hu)
HU (1) HUP0202757A3 (hu)
IL (2) IL148157A0 (hu)
IS (1) IS6275A (hu)
MX (1) MXPA02001764A (hu)
NO (1) NO322460B1 (hu)
NZ (1) NZ517221A (hu)
PL (1) PL353825A1 (hu)
RU (1) RU2296127C9 (hu)
SK (1) SK2512002A3 (hu)
UA (1) UA75871C2 (hu)
WO (1) WO2001012627A1 (hu)
ZA (1) ZA200201358B (hu)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1679313A3 (en) * 2001-02-21 2006-08-16 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
CA2442478C (en) * 2001-04-02 2010-02-02 Mark F. Bear Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
AU2002366388B2 (en) * 2001-12-18 2008-09-18 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1458383B1 (en) * 2001-12-18 2007-11-21 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
DE60334781D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
MXPA05001590A (es) * 2002-08-09 2005-05-23 Astrazeneca Ab Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
NZ538339A (en) * 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CA2521396A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20070026380A (ko) * 2004-02-18 2007-03-08 아스트라제네카 아베 융합된 헤테로시클릭 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
AU2005214380A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
CA2570318A1 (en) * 2004-06-30 2006-01-12 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP2008546836A (ja) * 2005-06-28 2008-12-25 アストラゼネカ アクチボラグ 新規な用途
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
BRPI0618636A2 (pt) 2005-11-08 2011-09-06 Hoffmann La Roche derivados de tiazolo [4,5-c]piridina
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
BRPI0709866B8 (pt) 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
WO2008028903A2 (en) * 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CA2661105C (en) 2006-09-07 2015-01-06 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
CA2662673A1 (en) 2006-09-21 2008-03-27 Martin Bolli Phenyl derivatives and their use as immunomodulators
PT2481410T (pt) 2007-01-31 2016-10-18 BIAL-PORTELA & Cª S A Derivados de nitrocatecóis como inibidores da comt administrados num regime posológico específico
BRPI0808789A2 (pt) 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
NZ583957A (en) * 2007-08-17 2011-09-30 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
NZ585775A (en) 2007-11-01 2011-12-22 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
CN101903356B (zh) * 2007-12-20 2013-05-22 拜耳知识产权有限责任公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
CA2714370C (en) 2008-02-07 2017-05-02 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
MX2010009645A (es) 2008-03-07 2010-09-28 Actelion Pharmaceuticals Ltd Derivados novedosos de aminometil benceno.
EP2276758B1 (en) 2008-03-17 2016-01-06 Bial-Portela & CA, S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol
CN102271682B (zh) 2008-10-31 2015-12-16 默沙东公司 用于治疗疼痛的p2x3受体拮抗剂
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
CA2755768A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2010229142A1 (en) 2009-03-23 2011-10-13 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010111059A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20120077854A1 (en) * 2009-04-13 2012-03-29 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
SG178042A1 (en) 2009-07-16 2012-03-29 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2665720B1 (en) 2011-01-19 2015-06-10 Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl derivatives
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CA3088684C (en) 2011-12-13 2021-10-26 Bial - Portela & C.A., S.A. Compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol in microparticulate form and its use in the treatment of parkinson's disease
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
US9232800B2 (en) 2013-02-15 2016-01-12 Monsanto Technology Llc 3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles and compositions and methods for controlling nematode pests
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
CA2981130C (en) 2015-05-20 2021-06-01 Cyrille Lescop Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CN107709301B (zh) 2015-06-23 2021-06-22 橘生药品工业株式会社 吡唑衍生物或其药理学上可接受的盐
EA201891948A1 (ru) * 2016-03-30 2019-04-30 Синнтаксис Аб Отрицательные аллостерические модуляторы метаботропного глутаматного рецептора 5 для применения в лечении зрелых повреждений головного мозга
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
SK282425B6 (sk) * 1995-04-21 2002-01-07 Neurosearch A/S Benzimidazolové zlúčeniny, farmaceutické zmesi obsahujúce tieto zlúčeniny a použitie týchto zlúčenín
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
CA2311131A1 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Also Published As

Publication number Publication date
ATE307129T1 (de) 2005-11-15
NZ517221A (en) 2004-01-30
MXPA02001764A (es) 2004-03-19
CZ2002599A3 (cs) 2002-06-12
RU2296127C2 (ru) 2007-03-27
WO2001012627A1 (en) 2001-02-22
ZA200201358B (en) 2003-07-30
NO322460B1 (no) 2006-10-09
HUP0202757A3 (en) 2006-03-28
CY1105253T1 (el) 2010-03-03
RU2296127C9 (ru) 2007-08-27
EP1210344A1 (en) 2002-06-05
SK2512002A3 (en) 2002-07-02
DE60023318T2 (de) 2006-07-20
UA75871C2 (en) 2006-06-15
BG106493A (en) 2003-01-31
CA2381975A1 (en) 2001-02-22
KR20020038731A (ko) 2002-05-23
BR0013427A (pt) 2002-07-30
KR100875222B1 (ko) 2008-12-19
NO20020823L (no) 2002-04-17
DK1210344T3 (da) 2006-03-06
IS6275A (is) 2002-02-18
JP2006143746A (ja) 2006-06-08
PL353825A1 (en) 2003-12-01
CN1313465C (zh) 2007-05-02
JP3790472B2 (ja) 2006-06-28
CN1379775A (zh) 2002-11-13
DE60023318D1 (de) 2006-03-02
EP1210344B1 (en) 2005-10-19
BG65586B1 (bg) 2009-01-30
AU6782400A (en) 2001-03-13
NO20020823D0 (no) 2002-02-19
JP2003507378A (ja) 2003-02-25
EE200200079A (et) 2003-06-16
IL148157A0 (en) 2002-09-12
ES2250177T3 (es) 2006-04-16
HK1047929A1 (en) 2003-03-14
AU780191B2 (en) 2005-03-03
IL148157A (en) 2007-07-04

Similar Documents

Publication Publication Date Title
HUP0202757A2 (hu) Metabotróp glutamát receptor antagonista heteropoliciklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása
JO2371B1 (en) 4-phenyl-pyridine derivatives
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
NZ502804A (en) 1-(N-(2-substituted phenyl)aminoalkyl)-piperazine derivatives
DE60324544D1 (de) Muskarin antagonisten
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DK0775118T3 (da) Benzimidazolderivater, der har dopaminerg aktivitet
BG105710A (en) 5ht1 antagonists for antidepressant therapy
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
UY27034A1 (es) Derivados de pirimidina
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
ATE374366T1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
MXPA04001977A (es) Antagonistas v de receptor ccr-3.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTRAZENECA AB, SE

Free format text: FORMER OWNER(S): NPS PHARMACEUTICALS, INC., US

FD9A Lapse of provisional protection due to non-payment of fees